Knockdown or depletion of EZH2 in tumor cells significantly enhanced the inhibitory effects of paclitaxel, docetaxel, and cisplatin on tumor cells, leading to a striking reduction in NRP1 levels (Figure 6A). Here, EZH2 is linked to neoplasm.